Octagam (Human Normal Immunoglobulin)

Octagam is an immunoglobulin therapy that acts on immune system deficiencies and dysregulation.

• Primary immunodeficiency diseases: provides replacement IgG antibodies to reduce infection frequency.
• Chronic immune thrombocytopenia (ITP): helps raise platelet counts and decrease bleeding risk.
• Multifocal motor neuropathy (MMN): improves muscle strength and functional ability.
• Kawasaki disease with coronary artery involvement: reduces inflammation and aneurysm progression.
• Primary humoral immunodeficiency post‑bone‑marrow transplant: supports immune reconstitution.

• Octagam supplies pooled human IgG antibodies that bind to a broad spectrum of pathogens and modulate immune activity. The infused IgG neutralizes toxins, opsonizes bacteria for phagocytosis, and engages Fc receptors to down‑regulate inflammatory cytokine production, thereby restoring humoral immunity and attenuating autoimmune processes.

Adverse reactions to Octagam vary with the infusion and patient factors.

Common Side Effects

• Headache
• Fever or chills
• Nausea or vomiting
• Fatigue
• Mild rash or itching
• Back or joint pain

Serious or Rare Side Effects

• Anaphylaxis or severe hypersensitivity
• Acute renal failure or hemolysis
• Thromboembolic events such as deep‑vein thrombosis
• Aseptic meningitis
• Severe hemolytic anemia
• Transfusion‑related acute lung injury (TRALI)

Before initiating Octagam, clinicians should evaluate patient history and monitor for specific risks.

• Renal function: assess baseline creatinine and adjust infusion rate in renal impairment.
• Cardiovascular status: monitor for fluid overload in patients with heart failure.
• Thrombotic risk: evaluate history of clotting disorders before therapy.
• Immunoglobulin A deficiency: test for anti‑IgA antibodies to avoid severe reactions.
• Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octagam may interact with other agents that affect immune function or renal clearance.

Major Interactions (Avoid)

• Live vaccines: concurrent use can diminish vaccine efficacy and increase infection risk.
• High‑dose aspirin or NSAIDs: may increase bleeding risk when combined with immunoglobulin‑induced platelet changes.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate fluid shifts; monitor volume status.
• ACE inhibitors: watch for additive renal effects.
• Anticoagulants: monitor coagulation parameters as immunoglobulin can affect clotting factors.
• Rituximab: may alter immunoglobulin kinetics; adjust monitoring.
• Corticosteroids: may increase infection susceptibility when combined.